Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia
David J. Kuter(Harvard University), Nichola Cooper(Imperial College London), Nikolay Tzvetkov(École Normale Supérieure de Lyon), Merlin Efraim(University Hospital St. Marina), Jiřı́ Mayer(Masaryk University), Vickie McDonald(University College London), Regan Burns(Principia Biopharma (United States)), Marek Trněný(Charles University), Olga Bandman(Principia Biopharma (United States)), Roman Hájek(University Hospital Ostrava), Eun‐Ju Lee(NewYork–Presbyterian Hospital), Milan Košťál(University Hospital Hradec Králové), Dolca Thomas(Pfizer (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders), Ann Neale(Principia Biopharma (United States))
Cited by 16
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
|Blood Advances|2019|1.1k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
|Leukemia|2008|808
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761